No Data
No Data
Changes in Hong Kong stocks | The collective decline in pharmaceutical stocks will improve the quality and expansion of pharmaceutical procurement, which is expected to form a national alliance for procurement
Pharmaceutical stocks fell collectively today. As of press release, Luye Pharmaceuticals (02186) fell 7.72% to HK$2.75; Kaituo Pharmaceutical-B (09939) fell 7.35% to HK$1.26; Zhongsheng Pharmaceuticals (01177) fell 5.75% to HK$2.95; and Cinda Biotech (01801) fell 4.61% to HK$38.3.
A record high! The total number of clinical trials exceeded 4,000 in 2023
According to the report, in 2023, the total number of clinical trials registered on the drug clinical trial registration and information disclosure platform surpassed 4,000 for the first time, reaching 4,300 (in terms of CTR), the highest total number of registrations in history, an increase of 26.1% over the total number of registrations in 2022.
開拓藥業-B:年報 2023
Kaituo Pharmaceutical-B (09939): Restitution of land use rights located in Pinghu City, Zhejiang Province, China
Kaituo Pharmaceutical-B (09939) issued an announcement. On April 25, 2024, the seller Kaituo Pharmaceutical (Zhejiang) had...
Kintor Pharmaceutical Concludes Phase II Clinical Trial for Androgenic Alopecia Treatment
Kintor Pharmaceutical (HKG:9939) said it completed the Phase II clinical trials for its Androgenic Alopecia treatment GT20029 in China, according to a Sunday filing on the Hong Kong bourse. The pharma
Changes in Hong Kong stocks | Pioneer Pharmaceutical-B (09939) opens nearly 15% GT20029 to treat male hair loss, China's phase II clinical trial reached the main end
Kaituo Pharmaceutical-B (09939) rose by nearly 15%. As of press release, it rose 14.94% to HK$1, with a turnover of HK$81,000.
No Data